Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BTN3A1 | O00481 | 3/20 | 0.49 |
| ▸ | MVD | P53602 | 4/20 | 0.42 |
| ▸ | FNTA | P49354 | 4/20 | 0.39 |
| ▸ | FNTB | P49356 | 3/20 | 0.39 |
| ▸ | GGPS1 | O95749 | 2/20 | 0.35 |
| ▸ | LPAR1 | Q92633 | 1/20 | 0.35 |
| ▸ | LPAR3 | Q9UBY5 | 1/20 | 0.35 |
| ▸ | PGGT1B | P53609 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2477274 | 0.88 | LPAR3 (0.33) | BTN3A1LPAR1LPAR3 | |
| SCHEMBL4993129 | 0.85 | BTN3A1 (0.49) | BTN3A1MVDFNTAFNTBGGPS1 | |
| SCHEMBL5586194 | 0.84 | LPAR3 (0.47) | LPAR1LPAR3 | |
| SCHEMBL155705 | 0.82 | BTN3A1 (0.53) | BTN3A1MVDFNTAFNTBGGPS1 | |
| SCHEMBL155704 | 0.82 | BTN3A1 (0.53) | BTN3A1MVDFNTAFNTBGGPS1 | |
| SCHEMBL3775300 | 0.81 | BTN3A1 (0.52) | BTN3A1MVDFNTAFNTBGGPS1 | |
| SCHEMBL21310680 | 0.81 | MVD (0.50) | BTN3A1MVDFNTAFNTB | |
| SCHEMBL22319792 | 0.81 | BTN3A1 (0.45) | BTN3A1MVDFNTAFNTBGGPS1 | |
| SCHEMBL22319797 | 0.81 | BTN3A1 (0.45) | BTN3A1MVDFNTAFNTBGGPS1 | |
| SCHEMBL27897700 | 0.79 | BTN3A1 (0.50) | BTN3A1MVDFNTAFNTBGGPS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2150258-A2 | IMPROVED METHODS OF USING PHOSPHOANTIGENS TOGETHER WITH INTERLEUKIN-2 FOR THE TREATMENT OF CANCER | Innate Pharma S.A. (FR) | 2010-02-10 | — | — | EP | disclosed |
| WO-2008146167-A2 | IMPROVED METHODS OF USING PHOSPHOANTIGENS TOGETHER WITH INTERLEUKIN-2 FOR THE TREATMENT OF CANCER | INNATE PHARMA S.A. (FR) | 2008-12-04 | — | — | WO | disclosed |